EAN 2026 | Recent approval of tolebrutinib in the EU for secondary progressive MS without relapses
Anthony Traboulsee, MD, University of British Columbia, Vancouver, Canada, reflects on the recent approval of tolebrutinib in the EU for secondary progressive multiple sclerosis (MS) without relapses. Prof. Traboulsee highlights that this approval addresses the unmet need of treating or slowing down progression. This interview took place at the 12th Congress of the European Academy of Neurology (EAN) in Geneva, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
The big unmet need in multiple sclerosis treatments is to stop or slow down progression as well as drive repair but right now we’re focused on trying to stop progression and so the BTK inhibitors with talibrutinib being the first approved in Europe for treatment of progressive MS is really a breakthrough for the field and I think we’re going to see more development and more success in the treatment of progressive MS in Europe as well as throughout the rest of North America and the world...
The big unmet need in multiple sclerosis treatments is to stop or slow down progression as well as drive repair but right now we’re focused on trying to stop progression and so the BTK inhibitors with talibrutinib being the first approved in Europe for treatment of progressive MS is really a breakthrough for the field and I think we’re going to see more development and more success in the treatment of progressive MS in Europe as well as throughout the rest of North America and the world.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
